Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference35 articles.
1. Abdel-Kahaar E, Winter S, Tremmel R, Schaeffeler E, Olbricht CJ, Wieland E, Schwab M, Shipkova M, Jaeger SU. The Impact of CYP3A4*22 on tacrolimus pharmacokinetics and outcome in clinical practice at a single kidney transplant center. Front Genet. 2019;26(10):871.
2. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol. 2008;2(4):693–702.
3. Arriens C, Teng YKO, Ginzler EM, Parikh SV, Askanase AD, Saxena A, et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res (Hoboken). 2022. https://doi.org/10.1002/acr.25007. (Epub ahead of print).
4. Askanase A, Hodge L, Birard V, Leher H. Early redutions in proteinuria with voclosporin treatment accross lupus nephritis biopsy classes. Pooled data from the AURA-LV and AURORA 1 trials. NDT. 2022;37(3):1820–1.
5. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, et al. PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011;11(12):2675–84.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献